Background Respiratory syncytial virus (RSV) remains the leading cause of serious viral bronchiolitis and pneumonia in infants and young children throughout the world. The burden of disease is ...

The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.

ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born ...

In addition to the respiratory arrest, sepsis, and cystitis, the autopsy found that Wilson also suffered from several more health issues at the time of his death, including obstructive sleep apnea ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) ...

About ENFLONSIA™ (clesrovimab-cfor) ENFLONSIA is Merck’s extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower ...

VIDEO: Researchers aboard the Antarctic icebreaker RSV Nuyina in the Southern Ocean send a weather balloon into the sky.

Chelsea Bekemeier spent a week at sea, travelling south-west towards the glacier, on board the Australian Antarctic Division's RSV Nuyina.

Jan, the SAEF team and the entire RSV Nuyina research crew are seeking to understand how changes to Antarctica will impact our future—all by looking to the past.

Respiratory viruses are the leading cause of lower respiratory tract infection (LRTI) and hospitalisation in infants and young children. Respiratory syncytial virus (RSV) is the main infectious agent ...

Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory infections for which effective treatment options remain limited. Herein, we employed a computational structure-based ...